Search PubMed⌕ Search

Biomedical subjects

P Stavem

Publications and source records attributed to P Stavem.

At least 55 records · Page 3Linked to original sources
PubMed1989

[Treatment of hairy cell leukemia].

Hairy cell leukemia is a rare leukemic variant with a relatively good prognosis. Treatment is indicated when the patient develops symptoms caused by cytopenia. When the spleen is palpable, the primary treatment should be splenectomy. When the spleen is not palpable and/or if the patient relapses after splenectomy, treatment with Alfa-Interferon is indicated. The place of deoxycoformycin in the treatment of hairy cell leukemia has not yet been established.

Adult↗
PubMed1989

[Fibromyalgia].

Explore the source record for details and available documents.

Complementary Therapies↗
PubMed1989

[Cytogenetic analysis in acute leukemia].

Leukemic cells often show clonal cytogenetic abnormalities. Some of these are strongly associated with certain morphological subgroups and seem to be of prognostic importance. Cytogenetic studies and molecular genetic investigations using recombinant DNA technology have contributed to our understanding of the development of leukemia. This article reviews earlier work on cytogenetic findings in acute leukemia, and adds our own experiences.

Acute Disease↗
PubMed1989

[Experiences of immunologic phenotyping in acute leukemia].

Phenotyping of leukemic cells with monoclonal antibodies usually confirms the morphological classification in acute lymphoblastic and acute myeloid leukemia. Immunological phenotyping gives a more detailed subclassification and may add information on the stage of differentiation of the leukemic cells. This may have prognostic implications, and in the future may influence the choice of treatment modalities. It is not unusual for the leukemic cells to carry both myeloid and lymphoid markers. For such leukemias the prognosis is poor. We describe our experience from immunological phenotyping of 46 acute myeloid and 35 acute lymphoblastic leukemias.

Acute Disease↗
PubMed1988

Leukemia in the central nervous system.

The frequency of central nervous system (CNS) leukemia was studied in patients aged 15-59 with acute leukemia, who had received induction treatment in the years 1971-1986. Twelve out of 103 patients with acute lymphoblastic leukemia (ALL) developed CNS leukemia in spite of prophylaxis consisting of intrathecal methotrexate. Ten out of 217 patients with acute myelogenous leukemia (AML) developed CNS leukemia. None had been given preventive treatment. Leukemic blasts with either M4 or M5 morphology appeared to increase the risk of CNS relapse. Treatment was adjusted to the clinical problem of each patient, but always included intrathecal methotrexate. Median survival after a diagnosis of CNS leukemia was 8 and 6 months in ALL and AML respectively, with bone marrow failure due to hematologic relapse as the leading cause of death. CNS leukemia, if properly treated, does probably not shorten survival. An active approach to diagnosis and treatment is therefore mandatory.

Adolescent↗
PubMed1988

Natural cytotoxicity in adult acute leukemia.

Natural cytotoxic activity was studied in 32 adult patients with acute non-lymphoid leukemia (ANLL) and 27 adult patients with acute lymphoblastic leukemia (ALL). Thirteen patients with active ANLL had a significantly reduced natural cytotoxicity in peripheral blood compared with that of healthy controls, 5.0 +/- 3.4 versus 27.1 +/- 11.5 (p less than 0.0005). Patients with ANLL in remission had a normal natural cytotoxicity (p greater than 0.05). Patients with active ANLL had a significantly reduced number of Leu-7-positive cells (p less than 0.001), while patients in remission had normal proportions of these cells (p greater than 0.05). Peripheral blood from patients with ALL showed reduced natural killer (NK) cell activity, both in active disease and in remission (p less than 0.0005). The percentage of Leu-11b (CD 16)-positive cells was increased in patients in remission from ALL (p less than 0.05). Bone marrow cells from patients with ALL in remission had a reduced natural cytotoxicity, 2.8 +/- 4.0 versus 16.3 +/- 9.0 in bone marrow controls (p = 0.01). In contrast, patients with ANLL in remission showed a normal bone marrow cytotoxicity (p greater than 0.05) while patients with active ANLL had a reduced NK cell activity (p less than 0.03). The low NK activity observed in leukemic patients may be of importance for the pathogenesis of the diseases. Acute non-lymphoid leukemia (ANLL) is a malignant disease of the multipotential hemapoietic stem cell. The stem cell is capable of differentiating into various cell lineages, i.e. erythroid, granulocytic, monocytic and megacariocytic cell lineages.(ABSTRACT TRUNCATED AT 250 WORDS)

Acute Disease↗
PubMed1988

Natural killer cells in chronic leukemia. Function and markers.

Twenty-two patients with chronic lymphocytic leukemia (CLL) and 14 patients with chronic myelogenous leukemia (CML) were studied with respect to natural killer (NK) cell activity and related cell markers (Leu 7 and Leu 11b). Significantly reduced NK cell activity was detected in peripheral blood from the patients with CLL. Similarly, a reduced number of cells with the markers Leu 7 and Leu 11b (CD 16) were detected in the same patients. Removal of the leukemic cells by centrifugation of cells forming rosettes with mouse erythrocytes led to an augmented, but not fully normalized, NK activity. This indicates that the low NK activity in CLL partly may be due to overgrowth of leukemic cells. However, in spite of the lymphocytic infiltration, the NK cell activity in the bone marrow of CLL patients did not differ significantly from that of normal controls. The patients with CML in the chronic phase as well as patients in the accelerated or blast phase also had a reduced NK activity. The finding that patients in the chronic phase had a reduced NK activity and normal numbers of Leu 11b (CD 16) positive cells, together with no detectable blasts in the peripheral blood, indicates that patients with CML may have an inherent NK cell defect. The highly reduced activity found in patients with the accelerated/blast form may in addition partly be due to overgrowth of leukemic cells. This low NK activity may be of importance in the development of chronic leukemia.

Adjuvants, Immunologic↗
PubMed1988

Ultrastructural identification of platelet surface glycoproteins and particle endocytosis with gold-labeled reagents.

Blood platet surface labeling was obtained by the use of the lectins concavalin A and wheat germ agglutinin. Colloidal gold particles coated with horseradish peroxidase and ovomucoid respectively were used as markers. Also erythrocytes and leukocytes were labeled. Using monoclonal antibodies against the platelet surface glycoproteins Ib and IIb-IIIa specific labeling of the platelets was obtained, whereas the red cells and the leukocytes were entirely free of labeling. With glutaraldehyde fixed platelets no gold particle uptake was observed. With unfixed normal platelets, however, surface membrane-associated particles were sometimes observed within the surface connecting canalicular system, and occasionally in small vesicles. In unfixed platelets from a patient with thrombocytopathia, possible platelet endocytosis of the membrane bound particles was observed with particles assumed to be transported via vesicles to granules probably representing lysosomal structures.

Antibodies, Monoclonal↗